Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke

Folia Biologica

Volumn 52, Issue 6, 2006, Pages 181-183

  Kurzepa, Jacek ^a   Szczepanska Szerej, A ^a   Stryjecka Zimmer, M ^a   Malecka Massalska, T ^a   Stelmasiak, Z ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

MMP 9; Simvastatin; Stroke; TIMP 1

Indexed keywords

GELATINASE B; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 33845881972     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Avolio, C., Ruggieri, M., Giuliani, F., Liuzzi, G. M., Leante, R., Ricco, P., Livera, P., Trojano, M. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 136, 46-53.
2. Brew, K., Dinakarpandian, D., Nagase, H., (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283.
3. Castellanos, M., Leira, R., Serena, J., Pumar, J.M., Lizasoain, I., Castillo, J., Davalos, A. (2003) Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34, 40-46.
4. Castillo, J., Ro, I. (2004) Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc. Dis. 17, suppl. 7-18.
5. Chandler, S., Coates, R., Gearing, A., Lury, J., Wells, G., Bone, E. (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201, 223-226.
6. Chandler, S., Miller, K. M., Clemens, J. M., Lury, J., Corkill, D., Anthony, D. C., Adams, S. E., Gearing, A. J. (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155-161.
7. Hartung, H. P., Kieseier, B. C. (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107, 140-147.
8. Kurzepa, J., Szczepańska-Szerej, A., Wojczal, J., Bielewicz, J., Stryjecka-Zimmer, M., Stelmasiak, Z. (2006) Influence of HMG-CoA reductase inhibitor (simvastatin) on serum matrix metalloproteinase-2 and -9 activity in acute ischemic stroke. Polish J. Environ. Stud. 15, 80-83.
9. Montaner, J. (2005) Treatment with statins in the acute phase of ischemic stroke. Exp. Rev. Neurother. 5, 211-221.
10. Montaner, J., Chacon, P., Krupinski, J., Millan, M., Hereu, P., Molina, C., Quintana, M., Alvarez-Sabin, J. (2004) Safety and efficacy of statins in the acute phase of ischemic stroke: the MISTICS trial. Stroke 34, 293.
11. Opdenakker, G., Van den Steen, P. E., Van Damme, J. (2001) Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22, 571-579.
12. Petty, M. A., Wettstein, J. G. (2001) Elements of cerebral mocrovascular ischaemia. Brain Res. Rev. 36, 23-34.
13. Planas, A. M., Sole, S., Justica, C. (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischaemia. Neurobiol. Dis. 8, 834-846.
14. Laws, P. E., Spark, J. I., Cowled, P. A., Fitridge, R. A. (2004) The role of statins in vascular disease. Eur. J. Vasc. Endovasc. Surg. 27, 6-16.